Overview


According to FutureWise analysis the market for Anti-Osteoporosis Therapy and Fracture Healing in 2023 is US$ 14.05 billion, and is expected to reach US$ 20.79 billion by 2031 at a CAGR of 5.00%.

Anti-osteoporosis therapy encompasses a comprehensive range of interventions designed to prevent and manage osteoporosis, a condition characterized by diminished bone density and quality, leading to an elevated risk of fractures. This therapeutic approach is paramount in preserving bone strength and minimizing the likelihood of fractures, particularly in vulnerable individuals. Common medications include bisphosphonates, which help to fortify bone density; selective estrogen receptor modulators (SERMs) that mimic estrogen's bone-protective effects; hormone replacement therapy (HRT) for postmenopausal women; denosumab, a monoclonal antibody that curbs bone resorption, and calcitonin, which inhibits bone breakdown and can alleviate pain associated with fractures. Additionally, nutritional and dietary considerations play a pivotal role in anti-osteoporosis therapy. 

Fracture healing is a biological process that occurs in stages. It begins with forming a hematoma at the fracture site, serving as a scaffold for subsequent healing. Following this, fibrocartilaginous callus formation occurs, wherein specialized cells generate collagen to form a soft callus around the fracture, providing initial stability. As healing progresses, the soft callus is gradually replaced by a hard callus composed of new bone tissue, further enhancing stability and facilitating complete fracture repair. This intricate process underscores the body's remarkable capacity for regeneration and recovery following a bone injury.

FutureWise Market Research has published a report that provides an insightful analysis of Anti-Osteoporosis Therapy and Fracture Healing Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Anti-Osteoporosis Therapy and Fracture Healing Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Eli Lilly and Company
  • Pfizer, Inc.
  • Amgen Inc.
  • Merck and Company Inc.
  • Novartis International AG
  • F. Hoffmann La Roche Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • GlaxoSmithKline Plc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Anti-Osteoporosis Therapy and Fracture Healing Market:

  • Biosciences Ltd's biosimilar drug, Denosumab, was approved by the Drug Controller General of India in August 2021 to treat adult osteoporosis.

The global demographic shift towards the older population contributes significantly to the disease burden of bone-related problems in geriatric patients, such as osteoporosis, and chances of fracture increase, driving the need for effective treatment and propelling the market. The surge in the prevalence of osteoporosis due to the sedentary lifestyle, hormonal challenges, and inadequate nutrition demands therapies to prevent them, driving the market growth. The government raises funds for research and development, which aids in producing new and innovative treatment modalities and medicines that work efficiently and effectively in osteoporosis and fracture healing, thus propelling the market. Raising awareness about osteoporosis and fracture recovery and its diagnosis and treatment fuels the market.

However, stringent regulatory policies in the approval of new drugs and therapies can pose a challenge to the market and restrain the market's growth. Adverse effects of these drugs, if taken in high doses, can cause toxicity and harm the individual's health, deterring the patient from further usage and can decline the market growth. The costly therapies and the treatment limit the accessibility and affordability for a certain number of populations with inadequate insurance coverage, constraining the market.
 

By Drug Type

  • Bisphosphonates
    • Osteoporosis
    • Others
  • Calcitonin
    • Osteoporosis
    • Others
  • Estrogen or Hormone Replacement Therapy
    • Osteoporosis
    • Others
  • Others
    • Osteoporosis
    • Others

By Route of Administration

  • Oral
  • Electric Vehicles
    • BEV
    • PHEV
  • Injectable

By Distribution Cannel

  • Hospital Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • E-Commerce

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022. The surge in the prevalence of osteoporosis, the presence of highly developed healthcare infrastructure, and expanded healthcare expenditure stabilizing the market in the region are various factors propelling the market growth in this region. Asia-Pacific is expected to witness the fastest-growing demand in the forecast period due to the increased geriatric population more prone to diseases like osteoporosis, propelling the market growth in this region. In addition, government initiatives and funds they raised for research and development are also driving the market

 

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Anti-Osteoporosis Therapy and Fracture Healing Market By Drug Type, By Route of Administration, By Distribution Cannel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Anti-Osteoporosis Therapy and Fracture Healing Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Anti-Osteoporosis Therapy and Fracture Healing Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Anti-Osteoporosis Therapy and Fracture Healing Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Anti-Osteoporosis Therapy and Fracture Healing Market, By Drug Type Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Bisphosphonates
         1.1. Osteoporosis
         1.2. Others
        2. Calcitonin
         2.1. Osteoporosis
         2.2. Others
        3. Estrogen or Hormone Replacement Therapy
         3.1. Osteoporosis
         3.2. Others
        4. Others
         4.1. Osteoporosis
         4.2. Others

  • 8.   Anti-Osteoporosis Therapy and Fracture Healing Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Oral
        2. Electric Vehicles
         2.1. BEV
         2.2. PHEV
        3. Injectable

  • 9.   Anti-Osteoporosis Therapy and Fracture Healing Market, By Distribution Cannel Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Hospital Pharmacies
        2. Drug Stores
        3. Retail Pharmacies
        4. E-Commerce

  • 10.   North America Anti-Osteoporosis Therapy and Fracture Healing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Anti-Osteoporosis Therapy and Fracture Healing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Anti-Osteoporosis Therapy and Fracture Healing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Anti-Osteoporosis Therapy and Fracture Healing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

    •   1. Eli Lilly and Company
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Pfizer, Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Amgen Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Merck and Company Inc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Novartis International AG
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. F. Hoffmann La Roche Ltd.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Teva Pharmaceuticals Industries Ltd.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. GlaxoSmithKline Plc.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11